2 active not recruiting, 1 unknown. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Unknown 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Renal Cell Carcinoma Recurrent: new trials by email Literature Review of Renal Cell Carcinoma Recurrent trials Research Report on Renal Cell Carcinoma Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Belzutifan, Cabozantinib - Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 2 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 118 | 2018-09-27 | 2024-12-20 |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) Belzutifan - Advanced Solid Tumors, Solid Tumor | Phase 1 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 120 | 2016-12-07 | 2026-10-26 |
| Study of the Combination of CM082 With Everolimus in Patients With mRCC CM082, Everolimus - Renal Cell Carcinoma Recurrent | Phase 1 | Unknown | AnewPharma | 18 | 2015-09-01 | 2018-01-10 |
Carcinoma, Renal Cell (2) · Kidney Neoplasms (2) · Glioblastoma (1) · Neoplasm Metastasis (1) · Recurrence (1)
Adenocarcinoma (2) · Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2)
belzutifan (2) · Everolimus (1) · cabozantinib (1) · vorolanib (1)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · AnewPharma (1)
China (1) · United States (1)
Jun Guo, M.D (1) · Xinan Sheng, M.D (1)